Compare Merck & Co., Inc. (MRK) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs SYSCO Corporation — how do they compare? Merck & Co., Inc. trades at $148 (market cap $363.98B), while SYSCO Corporation trades at $81.58 (market cap $39.08B). The key difference: Merck & Co., Inc. is far larger — about 9.3× SYSCO Corporation's market cap, and SYSCO Corporation pays the higher dividend (2.7%). Which is the better fit depends on your goals.
| MRK | SYY | |
|---|---|---|
Market Cap | $363.98B | $39.08B |
Sector | Health | Consumer Staples |
52-Week High | $156.43 | $91.16 |
52-Week Low | $77.60 | $69.30 |
Enterprise Value | $410.75B | $52.26B |
Dividend Yield | 2.3% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Sysco Corporation (SYY) trades at $79.84, down 0.26% with a bullish technical signal despite mixed moving averages. The company reported $81.37B in revenue for 2025 with a 2.08% net margin and maintains strong analyst support with 60% buy ratings. Recent news highlights AI efficiency initiatives and reaffirmed 2027 guidance, while the pending Jetro Restaurant Depot acquisition presents both growth opportunities and integration risks.
Sysco offers stable fundamentals with consistent revenue growth and dividend aristocrat status, but faces execution risks from its major acquisition and margin pressures. The stock trades below the $88.25 consensus target, suggesting potential upside if AI efficiency gains materialize and integration proceeds smoothly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
